AbbVie Inc.
ABBV Healthcare Drug Manufacturers General
AbbVie Inc.’s revenue for fiscal 2025 (year ended December 2025) was $61.2 billion, up 8.57% from fiscal 2024. In the quarter to June 2026, revenue grew 10.2%, EPS grew 290.4%, free cash flow fell 36.2% and total debt was flat, each against the same quarter a year earlier. Member of the S&P 500; dividend growth for ten consecutive years.
Follow ABBV
AbbVie Inc. (ABBV) Gross margin
AbbVie Inc.'s gross margin over the twelve months to 30 June 2026 was 71.5%, up 1.2 percentage points from fiscal 2025 (70.2%). Over the past ten years it has ranged from 62.4% (fiscal 2023) to 80.3% (fiscal 2015); the current reading is higher than 55% of that period. That is in line with the Drug Manufacturers General industry median of 72.8% and above the Healthcare sector median of 53.5%.
Gross margin, annual
Embed this chart
Annual newest first
| Period | Gross margin | Change (points) |
|---|---|---|
| FY2025 | 70.2% | 0.25 |
| FY2024 | 70.0% | 7.57 |
| FY2023 | 62.4% | (7.58) |
| FY2022 | 70.0% | 1.04 |
| FY2021 | 69.0% | 2.55 |
| FY2020 | 66.4% | (11.23) |
| FY2019 | 77.6% | 1.20 |
| FY2018 | 76.4% | 1.40 |
| FY2017 | 75.0% | (2.21) |
| FY2016 | 77.3% | (3.06) |
Quarterly newest first
| Period | Gross margin | Change (points) |
|---|---|---|
| Jun 2026 | 74.7% | 2.86 |
| Mar 2026 | 71.9% | (0.73) |
| Dec 2025 | 72.6% | 6.23 |
| Sep 2025 | 66.4% | (5.44) |
| 42 more quarters | Free account |
Against its own ten years
Gross margin against peers
| Company | Gross margin |
|---|---|
| LLY Eli Lilly and Company compare | 83.4% |
| AZN AstraZeneca PLC compare | 81.9% |
| GILD Gilead Sciences, Inc. compare | 79.6% |
| NVS Novartis AG compare | 74.7% |
| PFE Pfizer Inc. compare | 73.2% |
| MRK Merck & Co., Inc. compare | 73.0% |
| ABBV AbbVie Inc. | 71.5% |
| AMGN Amgen Inc. compare | 69.5% |
| JNJ Johnson & Johnson compare | 67.6% |
| Drug Manufacturers General industry median | 72.8% |
| Healthcare sector median | 53.5% |
| Market median | 46.2% |
What Gross margin is
Gross Margin tells an investor how much of each sale a company keeps after paying the direct costs of making or buying what it sells.
Gross Profit ÷ Revenue
More on ABBV
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement